Literature DB >> 17786383

Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients.

Haseeb Ahmad Khan1.   

Abstract

Diabetic patients with accompanied (but often unnoticed) dyslipidemia are soft targets of cardiovascular deaths. An early intervention to normalize circulating lipids has been shown to reduce cardiovascular complications and mortality. Glycated hemoglobin (HbA(1c)) is a routinely used marker for long-term glycemic control. This investigation is an attempt to evaluate the diagnostic value of HbA(1c) in predicting diabetic dyslipidemia. Venous blood samples were collected from 2,220 type 2 diabetic patients (ages, 35-91 years; male/female ratio, 1.07). The sera were analyzed for HbA(1c), fasting blood glucose (FBG), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL) and low-density lipoprotein cholesterol (LDL). The levels of HbA(1c) did not differ significantly between males (8.33 +/- 0.06%) and females (8.47 +/- 0.07%), whereas female patients had significantly higher FBG (10.01 +/- 0.13 mmol/l) than males (9.31 +/- 0.11 mmol/l). HbA(1c) showed direct and significant correlations with cholesterol, triglycerides and LDL and inverse correlation with HDL. Female diabetic patients had significantly higher levels of serum cholesterol (5.42 +/- 0.03 vs. 5.18 +/- 0.03 mmol/l) and HDL (1.32 +/- 0.01 vs. 1.12 +/- 0.01 mmol/l) as compared to males. There was no significant difference in triglycerides and LDL between the two genders. Older patients (>70 years) had significantly lower FBG, cholesterol, triglycerides and LDL. There was a linear and significant increase in triglycerides in the patients of both genders with impaired glycemic control. Both male and female patients with worse glycemic control (HbA(1c) > 9%) had significantly high cholesterol and LDL levels. Serum HDL showed a significant and inverse relationship with uncontrolled hyperglycemia in females but not in males. These findings clearly suggest that HbA(1c) can provide valuable supplementary information about the extent of circulating lipids besides its primary role in monitoring long-term glycemic control. Further studies are warranted to reinforce the potential of HbA(1c) as a biomarker for screening of high-risk diabetic patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786383     DOI: 10.1007/s00592-007-0003-x

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  17 in total

1.  Estimation of the contribution of biomarkers of different metabolic pathways to risk of type 2 diabetes.

Authors:  Jukka Montonen; Dagmar Drogan; Hans-Georg Joost; Heiner Boeing; Andreas Fritsche; Erwin Schleicher; Matthias B Schulze; Tobias Pischon
Journal:  Eur J Epidemiol       Date:  2010-12-28       Impact factor: 8.082

2.  Risk factors for clinically significant macular edema in a multi-ethnics population with type 2 diabetes.

Authors:  Ong Ming Jew; Mohammadreza Peyman; Tan Chen Chen; Subrayan Visvaraja
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

3.  Relationship between glycaemic control and lipid profile in type 2 diabetes mellitus patients in a low-resource setting.

Authors:  Ifeyinwa Dorothy Nnakenyi; Emeka Francis Nnakenyi; Elijah Joshua Parker; Nene Orizu Uchendu; Emeka Godwin Anaduaka; Lawrence Uchenna Ezeanyika
Journal:  Pan Afr Med J       Date:  2022-04-07

4.  Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes.

Authors:  Alessandra Gatti; Marianna Maranghi; Simonetta Bacci; Claudio Carallo; Agostino Gnasso; Elisabetta Mandosi; Mara Fallarino; Susanna Morano; Vincenzo Trischitta; Sebastiano Filetti
Journal:  Diabetes Care       Date:  2009-06-01       Impact factor: 19.112

5.  Dyslipidemia associated with poor glycemic control in type 2 diabetes mellitus and the protective effect of metformin supplementation.

Authors:  Yonas Mullugeta; Rajinder Chawla; Tedla Kebede; Yesehak Worku
Journal:  Indian J Clin Biochem       Date:  2012-06-06

6.  Glycosylated Haemoglobin (HbA1c) - A Marker of Circulating Lipids in Type 2 Diabetic Patients.

Authors:  Prabhavathi K; Kirthana Kunikullaya U; Jaisri Goturu
Journal:  J Clin Diagn Res       Date:  2014-02-03

7.  The effect of leptin promoter and leptin receptor gene polymorphisms on lipid profile among the diabetic population: modulations by atorvastatin treatment and environmental factors.

Authors:  Sayer I Al-Azzam; Omar F Khabour; Karem H Alzoubi; Raya N Alzayadeen
Journal:  J Endocrinol Invest       Date:  2014-06-24       Impact factor: 4.256

8.  Cardiac autonomic dysfunction in type 2 diabetes - effect of hyperglycemia and disease duration.

Authors:  Mika P Tarvainen; Tomi P Laitinen; Jukka A Lipponen; David J Cornforth; Herbert F Jelinek
Journal:  Front Endocrinol (Lausanne)       Date:  2014-08-08       Impact factor: 5.555

Review 9.  Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients.

Authors:  Shariq I Sherwani; Haseeb A Khan; Aishah Ekhzaimy; Afshan Masood; Meena K Sakharkar
Journal:  Biomark Insights       Date:  2016-07-03

10.  Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil.

Authors:  Ana Beatriz Valverde Mendes; João Antônio Saraiva Fittipaldi; Raimundo Celestino Silva Neves; Antônio Roberto Chacra; Edson Duarte Moreira
Journal:  Acta Diabetol       Date:  2009-08-05       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.